Remifentanil Hydrochloride Injection, Powder, Lyophilized, For Solution
FDA Label NDC 0143-9393

58 label sections · Submitted to the FDA by Hikma Pharmaceuticals Usa Inc. · Indications, Dosage, Usage, and Precautions

Structured Product Label

The following Structured Product Label (SPL) was submitted to the FDA by Hikma Pharmaceuticals Usa Inc. for the product Remifentanil Hydrochloride (NDC 0143-9393). This document serves as the official prescribing information, containing essential scientific data and clinical materials required for healthcare providers and patients.

This specific version of the label includes detailed information regarding warning: addiction, abuse, and misuse, 1 indications and usage, 2.1 important dosage and administration instructions, 2.2 general anesthesia, 2.3 continuation as an analgesic into the immediate postoperative period under the direct supervision of an anesthesia practitioner, 2.4 analgesic component of monitored anesthesia care, 2.5 discontinuation, 2.6 dosage modifications in geriatric patients, and other regulatory disclosures. Use the navigation below to review specific sections of the FDA submission.

Label Section Quick Index

* Please review the disclaimer below.